NRx Pharmaceuticals (NRXP) Stock Forecast, Price Target & Predictions
NRXP Stock Forecast
NRx Pharmaceuticals stock forecast is as follows: an average price target of $2.00 (represents a 16.28% upside from NRXP’s last price of $1.72) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
NRXP Price Target
The average price target for NRx Pharmaceuticals (NRXP) is $2.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $2.00 to $2.00. This represents a potential 16.28% upside from NRXP's last price of $1.72.
NRXP Analyst Ratings
According to 1 Wall Street analysts, NRx Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for NRXP stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
NRx Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 30, 2022 | Vernon Bernardino | H.C. Wainwright | $2.00 | $0.57 | 249.04% | 16.28% |
The latest NRx Pharmaceuticals stock forecast, released on Jun 30, 2022 by Vernon Bernardino from H.C. Wainwright, set a price target of $2.00, which represents a 249.04% increase from the stock price at the time of the forecast ($0.57), and a 16.28% increase from NRXP last price ($1.72).
NRx Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.72 | $1.72 | $1.72 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of NRx Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to NRx Pharmaceuticals's last price of $1.72. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 02, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 30, 2022 | H.C. Wainwright | - | Buy | Initialise |
NRx Pharmaceuticals's last stock rating was published by H.C. Wainwright on Aug 02, 2024. The company gave NRXP a "Buy" rating, the same as its previous rate.
NRx Pharmaceuticals Financial Forecast
NRx Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
NRx Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NRXP's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
NRx Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict NRXP's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than NRx Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
NRx Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-6.21M | $-6.21M | $-6.31M | $-6.31M | $-8.15M | $-7.73M | $-7.31M |
| High Forecast | $-6.21M | $-6.21M | $-6.31M | $-6.31M | $-8.15M | $-7.73M | $-7.31M |
| Low Forecast | $-6.21M | $-6.21M | $-6.31M | $-6.31M | $-8.15M | $-7.73M | $-7.31M |
| Surprise % | - | - | - | - | - | - | - |
NRx Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NRXP's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
NRx Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
NRx Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to NRXP last annual SG&A of $NaN (undefined).
NRx Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.59 | $-0.59 | $-0.60 | $-0.60 | $-0.78 | $-0.73 | $-0.69 |
| High Forecast | $-0.59 | $-0.59 | $-0.60 | $-0.60 | $-0.78 | $-0.73 | $-0.69 |
| Low Forecast | $-0.59 | $-0.59 | $-0.60 | $-0.60 | $-0.78 | $-0.73 | $-0.69 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, NRx Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NRXP previous annual EPS of $NaN (undefined).
NRXP Forecast FAQ
Is NRx Pharmaceuticals a good buy?
Yes, according to 1 Wall Street analysts, NRx Pharmaceuticals (NRXP) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of NRXP's total ratings.
What is NRXP's price target?
NRx Pharmaceuticals (NRXP) average price target is $2 with a range of $2 to $2, implying a 16.28% from its last price of $1.72. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will NRx Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for NRXP stock, the company can go up by 16.28% (from the last price of $1.72 to the average price target of $2), up by 16.28% based on the highest stock price target, and up by 16.28% based on the lowest stock price target.
Can NRx Pharmaceuticals stock reach $3?
NRXP's average twelve months analyst stock price target of $2 does not support the claim that NRx Pharmaceuticals can reach $3 in the near future.
What are NRx Pharmaceuticals's analysts' financial forecasts?
NRx Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-23.191M (high $-23.191M, low $-23.191M), average SG&A $0 (high $0, low $0), and average EPS is $-2.205 (high $-2.205, low $-2.205). NRXP's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-25.032M (high $-25.032M, low $-25.032M), average SG&A $0 (high $0, low $0), and average EPS is $-2.38 (high $-2.38, low $-2.38).